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The ins and outs of phosphate 
homeostasis
I Nemere1,2
A complication of chronic renal failure is hyperphosphatemia. An 
apparently straightforward manipulation to treat this — restriction 
of dietary phosphate — has proven that phosphate homeostasis is 
more complicated than we currently understand. This Commentary 
describes recent findings on novel regulatory factors that contribute 
to phosphate homeostasis.
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Th e study of phosphate homeostasis has 
received far less attention than calcium 
homeostasis for many decades. In part 
this is because phosphate is abundantly 
available in the diet whereas calcium is 
limited. However, there is increasing 
evidence that regulation of serum levels 
of phosphate through absorption in the 
intestine and excretion and reabsorption 
in the kidney is critical — for example, 
during growth, in hyperphosphatemia 
associated with chronic renal failure, 
and in X-linked hypophosphatemia.
In classical endocrine regulation, 
low serum phosphate induces the 
renal production of the seco-steroid 
hormone 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3). Low serum calcium 
signals the parathyroid glands to release 
parathyroid hormone (PTH), which 
likewise signals the kidney to increase 
production of 1,25(OH)2D3. Th is active 
metabolite of vitamin D acts to restore 
circulating mineral levels by increasing 
absorption in the intestine, reabsorption 
in the kidney, and mobilization of cal-
cium and phosphate from bone. Th us, 
chronic renal failure is associated with 
hyperparathyroidism, which in turn 
contributes to osteomalacia.
Another complication of chronic 
renal failure is hyperphosphatemia. 
Because the kidney is compromised in 
its ability to excrete phosphate, research 
has been devoted to assessing intestinal 
phosphate transport in nephrectomized 
rat model systems. Marks et al.1 (this 
issue) have, for the fi rst time, studied the 
eff ect of diet on such a model system in 
vivo. Uptake experiments using in situ 
intestinal loops showed that duodenal 
transport was greater than that in the 
jejunum but was unaff ected by nephrec-
tomy. Th e lower level of transport in the 
jejunum may be due to greater retention 
as measured in vitro. A low-phosphate 
diet tended to decrease transport in vivo 
but did not achieve a statistically signifi -
cant diff erence. Expression of Na/Pi-IIb 
cotransporter mRNA was also unaf-
fected by experimental manipulation 
in the intestine. In contrast, kidneys 
served as ‘positive’ controls in that this 
tissue showed diff erences in Na/Pi-IIa 
transporter mRNA levels with nephrec-
tomy and diet. Th e authors go on to note 
several therapeutic interventions that 
might be useful, such as the compound 
JTP-59557, a triazole derivative that 
inhibits Na/Pi-IIb.
Fibroblast growth factor 23 (FGF-23) 
has recently been recognized as a key 
mediator of phosphate homeostasis, its 
most notable eff ect being promotion of 
phosphate excretion. FGF-23 was discov-
ered to be involved in diseases such as 
autosomal dominant hypophosphatemic 
rickets, X-linked hypophosphatemia, and 
tumor-induced osteomalacia in which 
phosphate wasting was coupled to inap-
propriately low levels of 1,25(OH)2D3.
2 
In addition, mice in which the FGF-23 
gene has been deleted are hyperphos-
phatemic and have elevated serum 
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1,25(OH)2D3 levels.
3 Burnett et al.2 
have reported that FGF-23 is regulated 
by dietary phosphate in humans: phos-
phate restriction decreased FGF-23, and 
phosphate loading increased FGF-23. 
Unfortunately, in the nephrectomized 
rat model, dietary phosphate restriction 
did not reduce serum phosphate levels; 
this suggests that a further level of com-
plexity exists.
Several other observations can be 
considered in hyperphosphatemia 
associated with chronic renal failure. In 
a clinical study, Kates et al.4 found that 
serum phosphate in patients with mild 
to moderate chronic renal failure corre-
lated directly with serum PTH. Taken in 
conjunction with our fi nding that PTH 
enhances intestinal phosphate transport 
in perfused duodenal loops (reviewed by 
Khanal and Nemere5), these results sug-
gest that elevated PTH, with suffi  ciently 
permissive levels of 1,25(OH) 2D 3, might 
contribute to hyperphosphatemia.
In the normal kidney, the vitamin D 
metabolite 24,25-dihydroxyvitamin D3 
(24,25(OH)2D3) is produced when the 
organism is replete in 1,25(OH)2D3, 
calcium, and phosphate. Although some 
consider this to be an inactivation prod-
uct, there is extensive evidence from 
many laboratories that 24,25(OH)2D3 
is hormonally active, and physiologi-
cally relevant (reviewed by Khanal 
and Nemere5 and Farach-Carson and 
Nemere6). All of the observations 
reported have been made in vitamin D-
replete model systems. In the normal, 
vitamin D-replete animal, 1,25(OH)2D3 
stimulates rapid responses, includ-
ing enhanced phosphate and calcium 
transport in perfused duodenal loops, 
by activating a cell surface receptor. Th e 
1,25D3-MARRS (membrane-associated, 
rapid-response, steroid-binding) recep-
tor is distinct from the classical  vitamin 
D receptor, but identical to ERp57/Gr58 
(reviewed by Khanal and Nemere5). Th e 
protein has two thioredoxin domains 
that promote positive cooperativity in 
ligand binding (reviewed by Khanal and 
Nemere5) and may facilitate its ligand-
dependent translocation to the nucleus.7 
The metabolite 24,25(OH)2D3 is an 
endogenous inhibitor of 1,25(OH)2D3-
stimulated phosphate transport in 
the intestine (reviewed by Khanal and 
Nemere5). We have recently reported 
that 24,25(OH)2D3 decreases cata-
lase enzyme activity with concomitant 
increases in H2O2 (reviewed by Khanal 
and Nemere5). Increased levels of oxi-
dant, in turn, were found to impair 
binding of 1,25(OH)2D3 to the 1,25D3-
MARRS receptor (reviewed by Khanal 
and Nemere5). As evidence that this 
system functions in vivo, we fed animals 
antioxidant diets, to ameliorate the eff ect 
of 24,25(OH)2D3, and found increased 
absorption of phosphate in vivo, rela-
tive to that found with control diets.5 
Not surprisingly, serum 24,25(OH)2D3 
levels have been found to be decreased 
in chronic renal failure8 — which most 
likely contributes to hyperphosphatemia 
by removing feedback regulation of 
stimulated phosphate uptake.
A complicat ing fac tor  is  that 
24,25(OH)2D3 also decreases cal-
cium transport in the intestine9,10 and 
indeed has been found to be hypocal-
cemic in both dogs11 and rats.12 Oth-
ers have reported anabolic effects of 
24,25(OH)2D3 on bone and the clinical 
usefulness of 24,25(OH)2D3 in treat-
ing hyperparathyroidism (reviewed by 
Khanal and Nemere5 and Farach-Car-
son and Nemere6). Th us, the metabolite 
24,25(OH)2D3 may also have a thera-
peutic role in treating chronic renal 
failure. Figure 1 schematically depicts 
some of the relationships that have 
been established.
Th e factors that contribute to phos-
phate homeostasis are in need of more 
intensive investigation. Although two 
new hormones involved in this process 
— FGF-23 and 24,25(OH)2D3 — have 
been identifi ed by current workers in 
the fi eld, there are undoubtedly other 
regulatory substances that have yet to 
be discovered.
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Figure 1 | Schematic presentation of phosphate homeostasis. The kidney converts 25-hydroxy-
vitamin D3  (25(OH)D3) to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) when the organism is deficient 
in vitamin D, phosphate, and/or calcium. Hypocalcemia also signals the parathyroid glands to 
release parathyroid hormone (PTH), which stimulates 1α-hydroxylation of 25(OH)D3. 1,25(OH)2D3 
stimulates absorption of minerals from the intestine and reabsorption from the kidney. Fibroblast 
growth factor 23 (FGF-23) inhibits the formation of 1,25(OH)2D3 and promotes phosphaturia. 
When an animal is replete in calcium, phosphate, and 1,25(OH)2D3, the kidney shifts to producing 
24,25-dihydroxyvitamin D3 (24,25(OH)2D3), which blocks stimulated uptake of minerals from the 
intestine and PTH release from the parathyroid glands. Stimulation of bone resorption by PTH and 
1,25(OH)2D3 is not shown.
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